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Abstract
The involvement of secretin (SCT) and secretin receptor (SCTR) in regulating body water
homeostasis is well established. Identified as one of the vasopressin (Vp)-independent
mechanisms in fluid balance, SCT regulates aquaporin 2 (AQP2) in the kidney distal collect-
ing duct cells through activating intracellular cAMP production. This ability to bypass Vp-
mediatedwater reabsorption in kidney implicates SCT’s potential to treat nephrogenic dia-
betes insipidus (NDI). Research on NDI in the past has largely been focused on the search-
ing for mutations in vasopressin receptor 2 (AVPR2), while the functional relationship
between SCTR, AVPR2 and NDI remains unclear. Here, we demonstrate the interaction
between SCTR and AVPR2 to modulate cellular signaling in vitro. Interestingly, we show in
this report that upon heteromer formationwith SCTR, R137H, a NDI-causing AVPR2 mutant
that is defective in trafficking to cell surface, can functionally be rescued. Our data may pro-
vide an explanation for this clinically mild case of NDI, and insights into the pathological
development of NDI in the future.
Introduction
Water homeostasis is one of the most tightly regulated physiological events in the human body
[1]. In addition to the well-recognizedVp axis, the existence of Vp-independent mechanisms
in regulating water reabsorption is confirmed [2–12]. Among these, SCT was discovered to be
a neurohypophysial factor secreted alongside Vp in the posterior pituitary to control fluid bal-
ance by stimulating Vp expression and release from the hypothalamic paraventricular nucleus
[11]. SCT also stimulates water reabsorption in the kidney via activating the cAMP signaling
pathway and subsequently AQP2 trafficking in the kidney distal collecting duct cells [12]. X-
linkedNDI is a form of NDI caused by AVPR2 gene mutation on the X chromosome, and the
condition is characterized by very low urine osmolality plus marked increase in urine output
[13]. Over 170 different mutations were discovered leading to various degree of impairment in
kidney’s responsiveness to Vp stimulation [14]. There is no known cure for the disease; NDI
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patient management relies primarily on diuretics to reduce glomerular filtration rate, and sup-
plemented by tightly controlled intake of sodium and water [13]. A handful of novel treatment
strategies for NDI are currently under investigation. Notably, the vasopressin 1a receptor
antagonist SR 49059 was reported as being effective [15, 16]. In the past, elucidation of the
molecularmechanism of the disease focused heavily on AVPR2 [17, 18]. Most studies were
based on clinical reports of AVPR2 mutations, followed by cloning and functional characteri-
zation of the mutants [19–21]. However, these studies were conducted in heterologous system
expressing only the mutants [22–24]. There are recent evidences showing G protein-coupled
receptors (GPCRs) function as monomer and oligomers, with oligomerization of GPCRs mod-
ulating a number of receptor physiologies from cellular signaling cascade to receptor trafficking
[25, 26]. In light of SCT’s role in regulating body fluid, SCT was suggested as a potential treat-
ment option [27]. As SCTR and AVPR2 are co-localized in the kidney distal tubules [10], in
this report, we studied potential heteromer formation between SCTR with Vp receptors. We
found that SCTR specifically hetero-oligomerizeswith AVPR2, but not with AVPR1b. Both
SCTR and AVPR2 primarily utilize the cAMP signaling pathway, but SCTR is also known to
signaling through the calcium-IP3 pathway [28, 29]. We therefore investigated the functional
consequences of receptor oligomer formation, and found that the interaction between SCTR
and AVPR2 elicits differential receptor functions in vitro. Interestingly, we show here that
upon heteromer formation with SCTR, R137H, a NDI-causing AVPR2 mutant that is defective
in trafficking to cell surface, can functionally be rescued. Our data may provide an explanation
for this clinically mild case of NDI, and insights into the pathological development of NDI in
the future.
Results
In vitroBRET detection of mSCTR andmAVPR2 heteromer
As previously documented,mSCTR co-expresses with mAVPR2 in the kidney tubular cells
[10]. In this study, BRET saturation assay was used to confirm the specific heteromer forma-
tion of mSCTRwith mAVPR2 and mAVPR1a, but not mAVPR1b, in transfected cells (Fig 1).
This data provide evidence to show in vitro formation of specificGPCR heteromer formation
betweenmSCTR/mAVPR2 and mSCTR/mAVPR1a. Confocal imaging and fluorescence inten-
sity measurements were employed to ensure surface expression of the receptors were at compa-
rable degree (Fig 2).
mSCTR/mAVPR2 heteromer formationmodifies receptor function
When co-expressingmSCTR and mAVPR2 in vitro, upon stimulation of a graded concentra-
tion of SCT (1 pM to 10 μM), SCT-induced cAMP production was potentiated (Fig 3A; Emax
from 98.75 ±0.72 to 152.50±0.29% and EC50 from 51.44±9.92 to 2.49±0.25 nM), while no sig-
nificant changes were found in control cells co-expressingmSCTR and mAVPR1b. In contrast,
for Vp-induced cAMP (Fig 3B), co-expression of mSCTR reduced Emax from 89.75±5.92 to
46.23±2.88% and EC50 shifted from 0.64±0.15 to 84.20±21.80 nM. For intracellular calcium
response, cells transfected with mSCTR showed a typical sigmoidal response curve (Emax =
108.46±4.84%, EC50 = 34.95±10.93 nM) to SCT. However, in the presence of mAVPR2, the cal-
cium signals were mostly abolished (Fig 3C). In mAVPR2-transfected cells (Fig 3D), a response
was observedonly at 1 μM Vp, while the presence of mSCTR had no significant effect on maxi-
mal response nor potency. Quantitative RT-PCR data also suggest a comparable amount of
receptor transcripts when cells were transfected with one or both receptors (Fig 4). This data
support that signalingmodification observed is due to heteromer formation and not an unbal-
ance amount of receptors on the cell surface.
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Fig 1. mSCTR specifically oligomerizeswithmAVPR2, andmAVPR1a, but notmAVPR1b. Shown are the net
BRET ratios for CHO-K1 cells expressing a combination of mSCTR-Rlu donor andmAVPR-YFP acceptor
constructs. Saturable curves fromBRET assays were obtained for mAVPR2 and mAVPR1a, but not for mAVPR1b.
The data were mean±SEM from three to five independent experiments in triplicate.***, P<0.001. **, P<0.01. *,
P<0.05.
doi:10.1371/journal.pone.0163086.g001
Fig 2. Surface expressionofmAVPR1a, mAVPR1b, mAVPR2 andmSCTR are similar. Shown are
representative images of CHOK1 cells expressingmAVPR1a/mAVPR1b/mAVPR2 or mSCTR constructs. Surface
to intracellular fluorescence ratios were similar for these four types of cells. The data were mean±SEM from three
independent experiments with 5–6 ROIs per sample. Scale bar, 10μM.
doi:10.1371/journal.pone.0163086.g002
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Functional rescue of mAVPR2-R137H by co-expression with mSCTR
The R137Hmutant of AVPR2 is irresponsive to Vp as it constitutively binds to β-arrestin [15,
16, 21, 23, 24, 30–32], and as a result, this mutant resides in endocytotic vesicles [33]. Although
this mutant is non-functional, previous reports have associated it only with a mild form of NDI
[16, 21, 32, 33]. In consideration of the physical association of mSCTR and mAVPR2 in vitro,
the effects of co-expressing mSCTRwith mAVPR2 mutants were studied. In addition to
R137H, two other mutants, A89P and Q174R, that formmisfolded proteins incapable of reach-
ing the cell surface, were used as negative controls [34]. By BRET, mSCTR forms heteromer
with R137H, but not with A89P nor Q174R (Fig 5). In addition, confocal microscopy was
employed to visualize surface expression of receptors (Fig 6), with surface to intracellular fluo-
rescence signals calculated (Fig 7). Cells were transfected with wild type (WT) or mutated form
of mAVPR2-YFP, in the presence or absence of mSCTR. For WT, fluorescent signals were
observed evenly throughout the cell surface independent to mSCTR expression. R137Hmutant
was found predominately in endocytotic vesicles characteristic to its constitutive binding to β-
arrestin. However, upon co-expression with mSCTR, R137H was able to present to the cell
Fig 3. Signalingmodification as a specific consequence of SCTR-AVPR2 oligomerization.Percentage
changes in maximumcellular cAMP levels when cells were expressing a combination of mSCTR and/ormAVPR
constructs, comparing to cAMP responses in cells bearing only the native receptor to the ligand. A) SCT stimulated
a marked shift in Emax and potency in mSCTR in the presence of mAVPR2. No significant changes were observed
when the non-interactingmAVPR1b replacedmAVPR2. B) Similarly, Vp stimulated a notable reduction in Emax and
potency in mAVPR2 in the presence of mSCTR. The data were mean±SEM from three to five independent
experiments in triplicate.***, P<0.001. **, P<0.01. *, P<0.05. 10pM to 1μMSCT (panel C) or Vp (panel D) were
treated to cells with mSCTRand/ormAVPR2. Calcium response curves are presented as percentages of maximal
changes in RFU of cells expressing mSCTR or mAVPR2 only and stimulatedwith 1μMpeptide. Except for cells
with mSCTRonly, a marked increase in cellular calcium response can only be seen at 1μMpeptide concentration.
Data were obtained from three individual experiments with 5–6 ROIs per dose.
doi:10.1371/journal.pone.0163086.g003
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surface. On the other hand, A89P and Q174R mutants were trapped in the cytoplasmwith or
without mSCTR. As an additional control to confirm the localization of A89P and Q174R
mutants within the ER, immunofluorescencewas performed using antibody targeting the ER
specificmarker calreticulin, conjugated with Alexa Fluor1 488 (Fig 8). In order to assay for
Fig 4. Comparable transcript levels ofmSCTR andmAVPR2 in CHOK1 cells transiently transfectedwith
combinations of mSCTR andmAVPR2 by quantitativereal-timePCR. The total receptor gene transcript levels
were compared to the internal house-keeping control GAPDH by the 2 ΔΔ ct method. There is no significant
difference among the groups. mSCTR/pcDNA3.1, 1ugmSCTR plasmidwith 1ug pcDNA 3.1 empty vector;
mSCTR/mAVPR2, 1ug receptor plasmid each; pcDNA3.1, 2ug pcDNA3.1;mAVPR2/pcDNA3.1, 1ugmAVPR2
plasmid with 1ug pcDNA 3.1. Data are presented as means ± SEM from three independent experiments in
duplicate. ns, not significant.
doi:10.1371/journal.pone.0163086.g004
Fig 5. Oligo-complex formation rescues the constitutively endocytosedmAVPR2 mutant R137H.The
constitutively β-arrestin bound R137Hmutant of mAVPR2 is largely endocytosed. With co-expression of
mSCTR, however, an increase in net BRET signal suggests rescue of the R137Hmutant to the cell surface
by heterocomplex formation. Themutations of A89P or Q174R, which lead to improper folded, non-surface
reaching receptors, cannot be rescued by the formation of heteromer. Significance level was calculated
against themAVPR1b control. The data were mean±SEM from three to five independent experiments in
triplicate.***, P<0.001.
doi:10.1371/journal.pone.0163086.g005
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the affinity betweenWT/mutant receptors with β-arrestin, BRET studies were performed using
Rlu- taggedAVPR2s and YFP tagged β-arrestin. In native state, the R137Hmutant showed a
significantly higher affinity to β-arrestin, comparing to theWTAVPR2. However, such affinity
can be significantly reduced when SCTR is coexpressed. The other forms of mutants could not
be rescued by SCTR co-expression (Fig 9A). As a positive control, 1 μM Vp was treated to the
cells and BRETmeasured 10 minutes after peptide stimulation (Fig 9B). As part of the internal-
ization process, β-arrestin binding to the receptors resulted in an increase in BRET signal for
theWT AVPR2, but not in the other mutants that were not functional. Nonetheless, with
SCTR co-expression, the R137Hmutant showed increased β-arrestin compared to the no
Fig 6. Rescue of the constitutively endocytosedR137HmAVPR2 mutant upon co-expression of
mSCTR.Representative confocal images indicating the cellular location of mAVPR2-YFP receptors. TheWT
mAVPR2 is evenly distributed in the cell surface regardless of mSCTR co-expression. The R137Hmutant is
predominantly located in the intracellular endocytotic vesicles. Vesicular retention is not observedwhen
mSCTR is co-transfected. The A89P and Q174Rmutants cannot be rescued by mSCTR co-expression and
remain intracellular. Scale bar, 10μM.
doi:10.1371/journal.pone.0163086.g006
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peptide situation. This suggest also the rescue of the receptor to the cell surface and hence the
correct functioning of the receptor. Combing the BRET data and the confocal images showing
the surface expression of receptor, it suggests that R137H, in the presence of SCTR, can be pre-
sented to the cell surface. On top of rescuing R137H to the cell surface, such surface expression
brought about the partial functioning of the receptor in response to both SCT and Vp stimula-
tion. The signalingmodifications inWTAVPR2 was found also in the SCTR-rescued R137H
mutant (Fig 10).
Discussion
The signalingmodification observed in the present study illustrates the importance of GPCR
heteromer in affecting cellular physiology. More notably, our data exemplifies a second
instance of cross-class GPCR heteromer formation in addition to the previously elucidated
SCTR-AT1aR heteromer [35]. Since both AT1aR and AVPR2 pose key roles in regulation of
body water, heteromer formation with these receptors implicates SCTR as an important part-
ner in fluid balance.
Functional rescue studies of the R137Hmutant of AVPR2 were exclusively based on phar-
macological chaperone [15, 16], and in vitro studies of the mutant were performed in the
absence of SCTR [16, 21, 32, 33]. NDI is a rare disease but can be caused by over 170 of
Fig 7. Surface to intracellular fluorescence ratio for cell expressingWT/mutantAVPR2 with or without
SCTR co-expression.The presence of SCTR increased the amount of fluorescenceon the cell surface in cell
expressing R137HAVPR2 taggedwith YFP, indicating a rescue of the mutant receptor. The data were mean±SEM
from three independent experiments from 5–6 ROIs per sample.
doi:10.1371/journal.pone.0163086.g007
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mutations in AVPR2 [14], clinical information is scarce, especially those specifyingR137H
mutation. In a previous report, the R137H patient showed distinctive readings for urine vol-
ume and urine osmolality compared withW164S and 185_193del patients [15]. Baseline urine
volume and osmolality for the R137H patient were 125ml/30min and 200mOsm/kg respec-
tively, while the two other patients were at 500ml/30min, 70mOsm/kg and 350ml/30min,
70mOsm/kg, respectively. This discrepancy in clinical parameters was noticed also by the
authors, but no explanation was given. In another report involving two 8-year-old boys [31],
urine output and osmolality for delG102 were 10–12 L/day and 100 mOsm/kg, and for R137H
were>7L/day and 122mOsm/kg. It is difficult to compare various reports regarding the
R137Hmutant [15, 31, 33], due to age differences in patients and that not all relevant clinical
figures (weight, plasma osmolality, plasma glucose content) were given. However, with the
textbook definition of complete NDI having an urine osmolality of<100mOsm/kg [13],
together with the general observation of elevated urine production in NDI caused by other
mutations [31, 33, 34, 36, 37]. The R137Hmutation paradoxically causes a less severe case of
NDI, and our data here provide plausible explanations to this illusive situation. Concurrent
with previous reports suggesting SCT and SCTR playing an important role in the water balance
axis, our findings consolidate this idea. In the past, polypeptide fragment of AVPR2 and
AVPR1a antagonist SR 49059 were reported as effective agents in rescuing AVPR2 mutants
[15, 16, 38, 39], the current study suggests SCTR chaperone or SCT analogues as novel treat-
ment alternatives for some forms of NDI.
Fig 8. Localization of A89P/Q174Rmutant within the ER.Using the ER specific marker Anti-calreticulin
antibody conjugated with Alexa Fluor1 488, the A89P and Q174RAVPR2 mutants were determined to be resided
within the ER. Scale bar, 10μM.
doi:10.1371/journal.pone.0163086.g008
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Methods
Receptor constructs
The donor protein in bioluminescence resonance energy transfer (BRET) assay, mouse SCTR
tagged at the carboxyl-terminuswith Renilla luciferase construct (mSCTR-Rlu) was the generous
gift of Prof. L.J. Miller from previous study [35]. Mouse AVPR 1a, 1b and 2, as well as β-arrestin
(mAVPR1a, mAVPR1b, and mAVPR2; β-arrestin) were tagged at carboxyl end with yellow fluo-
rescent protein (YFP) by cloning the respective cDNA into the vector pEYFP-N1 (Promega,
Fitchburg, WI) as acceptor proteins in BRET (mAVPR1a/AVPR1b/AVPR2-YFP). Untagged
mSCTR,mAVPR1a, mAVPR1b, and mAVPR2 were cloned into the vector pcDNA3.1(+).
mAVPR2 mAVPR2 mutants were generated by site-directedmutagenesis using the QuikChange
II Site-DirectedMutagenesis Kit (Agilent Technologies, Santa Clara, CA). The primers were
designed using the online QuikChange Primer Design program (Agilent Technologies). The Rlu-
taggedAVPR2 mutants were obtained by cloning the receptor into the Rlu-plasmid.
Cell culture and transfection
CHO–K1 cells were purchased from ATCC (Manassas, VA). Cells were propagated in Mini-
mum Essential Medium (MEM), pH 7.3 (Gibco, CA) supplemented with 10% (v/v) fetal bovine
serum (FBS) (Gibco) in presence of 1% (v/v) penicillinG (100 U/ml) and streptomycin
(100 μg/ml) (Invitrogen, CA), cultured at 37°C with 5% CO2 (Linde, HK). For conducting
BRET and cAMP experiments, cells were plated on 6-well tissue culture plates (Nunc) at a den-
sity of 3×105 cells per well 24 hrs before transient transfection. For calcium assays and confocal
Fig 9. Rescue of R137Hmutant by SCTR as reflectedby reducedaffinity to β-arrestin.The affinity between
WT or mutant AVPR2 with β-arrestin were determined by BRET, using AVRP2 taggedwith Rlu and β-arrestin
taggedwith YFP. A) In the native state, the R137Hmutant shows significantly higher affinity to β-arrestin than the
WT AVPR2. While the two othermutants, A89P and Q174R, showed slightly higher BRET than theWT receptor,
but the increasewas not significant.Upon co-expression of SCTR, β-arrestin affinity of R137Hwas significantly
reduced compared to the scenariowhen no SCTRwas present. B) BRET was measured at 10 min after addition of
1μMVp to stimulate receptor internalization. WT AVPR2 showed increase affinity to β-arrestin, but not the R137H
mutant without SCTR co-expression. With SCTR, R137H demonstrated increasedβ-arrestin binding, suggesting
functional rescue of the receptor. Data are presented as means±SEM from three independent experiments in
duplicate. ***, P<0.001, **, P<0.01.
doi:10.1371/journal.pone.0163086.g009
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imaging, cells were seeded on 35mm glass bottom dishes coated with poly-d-lysine (MatTek
Corporation,Ashland, MA) at a density of 1×105 cell per well 24 hrs before transfection. Trans-
fection of cells was done using the ViafectTM reagent (Promega) according to manufacturer’s
recommendation.
Fig 10. mSCTR-rescuedmAVPR2-R137H functions similarly toWT receptor. In both SCT (panel A) and Vp
(panel B) events, mSCTRwas able to rescue the functioning of themutatedmAVPR2-R137H. AlignedwithWT
AVPR2, rescued AVPR2 mutant could potentiateSCT-induced cAMP. Note that although oligomer formation
restoresVp’s ability in stimulating the R137H receptor, the effect of oligomer formation blunting cAMP response
elicited by Vp was still in place. The data were mean±SEM from three to five independent experiments in triplicate.
***, P<0.001. **, P<0.01.
doi:10.1371/journal.pone.0163086.g010
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Quantitative Real Time PCR
Quantitative real time PCR experiments were performed using Taqman reagents according to
manufacturer’s protocol (Invitrogen). Gene transcript levels were compared to the internal
house-keeping control GAPDH by the 2 ΔΔ ct method. The probes were as follows, SCTR:
Mm1290794_m1; AVPR2: Mm00517071_m1.
BRET assays
For saturation BRET assays, 1μg of the donor mSCTR-Rlu construct was transfected with
graded amount (0.0–3.0μg) of acceptor constructs. An appropriate amount of pcDNA3.1
empty vector was added to maintain the total amount of DNA transfected be 4μg in all assays.
BRET assays were performed 48 hrs after transfection. Cells were lifted using the non-enzy-
matic cell dissociation reagent Versene (Invitrogen) and washed in Hanks’ Buffered Saline
Solution (HBSS, Invitrogen). After counting using an automated cell counter (LUNA; Logos
Biosystems, Inc., S. Korea), 100,000 cells were added to each well of a black 96-well test plate
(SPL life sciences, S. Korea). Renilla luciferase substrate Coelenterazine-h (Promega) was
added to each well to a final concentration of 5μM. Bioluminescence emission was immediately
measured at 440–500 nm (luciferin) and 510–590 nm (YFP) using a VICTOR X4Multilabel
Plate Reader (PerkinElmer, Inc., Waltham, MA). BRET ratios were calculated as long (510–
590) / short (440–500) emission signals. Net BRET ratio was the BRET ratio of experimental
group minus the BRET ratio of the negative control which expressed donor molecule only.
cAMP assays
Cells were transfectedwith a combination of non-tagged receptors, at 1μg each. cAMP assay was
performed 48 hrs after transfection using the LANCE cAMP kit (PerkinElmer) according to
manufacturer’s protocol. Dose-dependent cAMP responses were assayed by treatment of mouse
SCT (GenScript) or mouse Vp (Phoenix Pharmaceuticals, Inc., Burlingame, CA) at concentra-
tions from 1 pM to 10 μM for 30 mins. Basal cellular cAMPwas measured without peptide treat-
ment. The Time-Resolved Fluorescence signal was detected in Victor X4 (PerkinElmer).
Calcium assays
Transfected cells having 1μg each of non-tagged receptors were rinsed twice in solution α (HBSS
with 2.5mMprobenecid, 250mMNaOH, adjusted to pH 7.4 by HCl) 24 hrs after transfection.
Loading of cells with cell permeant Fluo-4, AM (Invitrogen) was done at 1 μM Fluo-4, AM diluted
in solution α containing 0.003% Pluronic1 F-127 (Invitrogen) for 30 mins at room temperature.
The cells were rinsed twice in solution α and allowed to incubate at room temperature for 30 mins
before fluorescence signal was monitored. Fluorescence signal was measured on an LSM 710 NLO
Confocal Laser ScanningMicroscope (Carl ZeissMicroscopy GmbH, Jena, Germany) using a
Plan-Neofluar 20x/0.50 Ph2 objective. The machine was set to excite the samples through an
argon laser (LASOS LasertechnikGmbH, Jena, Germany) at 488 nm and record 493–622 nm
emission in a time seriesmanner. The pinhole was set at 44μm and pixel dwell at 1.58 μs. An 8-bit
framewas captured every two seconds for 150 seconds. Cell viability was assayed by stimulating
the cells with 60 mMKCl at the end of the experiment. The changes in relative fluorescence unit
(RFU) were calculated by selecting at least five regions of interest (ROI) from each experiment.
Fluorescence confocal imaging
Cells were transfected with 1μg YFP taggedWTmAVPR2 receptors or mutant receptors, plus
or minus 1μg mSCTR. 24 hrs post transfection, cells were rinsed with HBSS and fixed in
Secretin and Nephrogenic Diabetes Insipidus
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paraformaldehyde at room temperature for 20 mins. They were then mounted using the
Fluoro-Gel mounting medium (ElectronMicroscopy Sciences,Hatfield, PA). Fluorescence sig-
nal was measured on the same confocal microscope and objective. The machine was set to
excite the samples at 514 nm and record 519–621 nm emission. The pinhole was set at 44μm
and pixel dwell at 12.6 μs. Signals were recorded as 12-bit images. Surface to intracellular fluo-
rescence ratio was calculated using the software ImageJ (NIH, US).
Immunofluorescence staining
Samples preparation were the same as fluorescence confocal imaging until the mounting step.
After fixation, samples were blocked with 1% BSA in PBST (PBS +0.1% Tween 20) for 30 min
at room temperature. Samples were then incubated overnight at 4°C with 1:100 Anti-Calreticu-
lin antibody [EPR3924]—ERMarker (Alexa Fluor1 488) (Abcam, Cambridge,MA). After
three wash of PBS, Fluoro-Gel mounting were done before image acquisition.
Statistical analysis
Statistical analysis and graph plotting were done by the computer software PRISM (version
5.03; GraphPad, San Diego, CA). All data were presented as means ± SEM from at least three
independent experiments, each in duplicate or triplicate. Data were analyzed based on the
assumption that the sample data followed a normal distribution. One-way ANOVA followed
by a Dunnett’s test was used to compare experimentalmeans against the control means for sig-
nificance levels. Saturation BRET curveswere fitted using the one-site total binding model.
Dose response curveswere fitted using the agonist stimulation model (three parameters) and
values for maximal response (Emax) and the half maximal effective concentration (EC50) were
obtained from the curves.
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